Table 5.
The role of miR-145 enhances cancer therapy sensitivity and reverse resistance.
| Therapy | Cancer Type | Downstream Targets | Reference |
|---|---|---|---|
| 5-FU | Colorectal cancer | RAD18 | [108] |
| Esophageal carcinoma | REV3L | [110] | |
| Bortezomib | Multiple myeloma | HDAC4 | [111] |
| Cisplatin | Gastric cancer | APRIL | [112] |
| Ovarian cancer | c-Myc | [113] | |
| Gallbladder cancer | MRP1 | [114,115] | |
| Nasopharyngeal carcinoma | SOX2 | [116] | |
| Non-small cell lung cancer | MRP1 and P-gp | [117] | |
| CDK6 | [118] | ||
| KLF4 | [119] | ||
| Esophageal carcinoma | MRP1 and P-gp | [106] | |
| Docetaxel | Lung adenocarcinoma | FSCN1 | [120] |
| Prostate cancer | AKAP12 | [103] | |
| Doxorubicin | Hepatocellular carcinoma | SMAD3 | [121] |
| Breast cancer | MRP1 | [122] | |
| Erlotinib | Non-small cell lung cancer | EGFR | [123] |
| Gefitinib | Non-small cell lung cancer | ADAM19 | [105] |
| Gemcitabine | Bladder cancer | HMGA2 and KLF4 | [124] |
| Pancreatic adenocarcinoma | P70S6K1 | [125] | |
| Imatinib | Hepatocellular carcinoma | P-gp and BCRP | [126] |
| Oxaliplatin | Colorectal cancer | GPR98 | [127] |
| MRP1 | [128] | ||
| Paclitaxel | Ovarian cancer | Sp1 and CDK6 | [65] |
| Radiation | Cervical cancer | HLTF | [129] |
| Colorectal cancer | KLF4 and c-Myc | [107] | |
| Esophageal carcinoma | P70S6K1 | [130] | |
| Prostate cancer | RAD51, Mcl1, Par-4, and PARP1 | [127] | |
| Hepatocellular carcinoma | RAD18 | [131] |